Change in Mean Duration of Therapy Following Implementation of Antibiotic Time-out
| . | Intercept Parameters (Indicative of Immediate Change) . | Slope Parameters (Indicative of Long-Term Change) . | ||||||
|---|---|---|---|---|---|---|---|---|
| Antibiotic . | Baseline Value . | Calculated Change . | 95% CI . | P Value . | Baseline Value . | Calculated Change . | 95% CI . | P Value . |
| Targeted antibiotics | ||||||||
| Daptomycin | 6.18 | −0.89 | −1.38 to −.41 | <.001 | −0.01 | 0.01 | −.01 to .03 | .291 |
| Linezolid | 6.21 | −0.89 | −1.27 to −.52 | <.001 | −0.01 | 0.00 | −.01 to .02 | .741 |
| Meropenem | 7.58 | −0.97 | −1.39 to −.56 | <.001 | −0.01 | 0.00 | −.01 to .02 | .669 |
| Tigecycline | 9.03 | −1.41 | −2.19 to −0.63 | .001 | 0.00 | −0.01 | −.03 to .02 | .724 |
| Vancomycin | 4.63 | 0.09 | −.10 to .29 | .342 | −0.01 | −0.04 | −.01 to .00 | .313 |
| Nontargeted antibiotics | ||||||||
| Cefepime | 5.34 | 0.15 | −.09 to .39 | .216 | −0.01 | −0.01 | −.02 to −.00 | .047 |
| Ceftazidime | 8.26 | −0.67 | −2.00 to .66 | .322 | 0.04 | −0.03 | −.08 to .15 | .177 |
| Piperacillin-tazobactam | 5.62 | −0.08 | −.31 to .16 | .523 | −0.02 | 0.01 | .00 to .02 | .139 |
| Ertapenem | 3.02 | −0.09 | −.47 to .29 | .656 | −0.02 | 0.03 | .02 to .05 | <.001 |
| . | Intercept Parameters (Indicative of Immediate Change) . | Slope Parameters (Indicative of Long-Term Change) . | ||||||
|---|---|---|---|---|---|---|---|---|
| Antibiotic . | Baseline Value . | Calculated Change . | 95% CI . | P Value . | Baseline Value . | Calculated Change . | 95% CI . | P Value . |
| Targeted antibiotics | ||||||||
| Daptomycin | 6.18 | −0.89 | −1.38 to −.41 | <.001 | −0.01 | 0.01 | −.01 to .03 | .291 |
| Linezolid | 6.21 | −0.89 | −1.27 to −.52 | <.001 | −0.01 | 0.00 | −.01 to .02 | .741 |
| Meropenem | 7.58 | −0.97 | −1.39 to −.56 | <.001 | −0.01 | 0.00 | −.01 to .02 | .669 |
| Tigecycline | 9.03 | −1.41 | −2.19 to −0.63 | .001 | 0.00 | −0.01 | −.03 to .02 | .724 |
| Vancomycin | 4.63 | 0.09 | −.10 to .29 | .342 | −0.01 | −0.04 | −.01 to .00 | .313 |
| Nontargeted antibiotics | ||||||||
| Cefepime | 5.34 | 0.15 | −.09 to .39 | .216 | −0.01 | −0.01 | −.02 to −.00 | .047 |
| Ceftazidime | 8.26 | −0.67 | −2.00 to .66 | .322 | 0.04 | −0.03 | −.08 to .15 | .177 |
| Piperacillin-tazobactam | 5.62 | −0.08 | −.31 to .16 | .523 | −0.02 | 0.01 | .00 to .02 | .139 |
| Ertapenem | 3.02 | −0.09 | −.47 to .29 | .656 | −0.02 | 0.03 | .02 to .05 | <.001 |
All values correspond to a linear combination of parameter estimates for the before and after values of the segmented regression analysis.
Abbreviation: CI, confidence interval.
Change in Mean Duration of Therapy Following Implementation of Antibiotic Time-out
| . | Intercept Parameters (Indicative of Immediate Change) . | Slope Parameters (Indicative of Long-Term Change) . | ||||||
|---|---|---|---|---|---|---|---|---|
| Antibiotic . | Baseline Value . | Calculated Change . | 95% CI . | P Value . | Baseline Value . | Calculated Change . | 95% CI . | P Value . |
| Targeted antibiotics | ||||||||
| Daptomycin | 6.18 | −0.89 | −1.38 to −.41 | <.001 | −0.01 | 0.01 | −.01 to .03 | .291 |
| Linezolid | 6.21 | −0.89 | −1.27 to −.52 | <.001 | −0.01 | 0.00 | −.01 to .02 | .741 |
| Meropenem | 7.58 | −0.97 | −1.39 to −.56 | <.001 | −0.01 | 0.00 | −.01 to .02 | .669 |
| Tigecycline | 9.03 | −1.41 | −2.19 to −0.63 | .001 | 0.00 | −0.01 | −.03 to .02 | .724 |
| Vancomycin | 4.63 | 0.09 | −.10 to .29 | .342 | −0.01 | −0.04 | −.01 to .00 | .313 |
| Nontargeted antibiotics | ||||||||
| Cefepime | 5.34 | 0.15 | −.09 to .39 | .216 | −0.01 | −0.01 | −.02 to −.00 | .047 |
| Ceftazidime | 8.26 | −0.67 | −2.00 to .66 | .322 | 0.04 | −0.03 | −.08 to .15 | .177 |
| Piperacillin-tazobactam | 5.62 | −0.08 | −.31 to .16 | .523 | −0.02 | 0.01 | .00 to .02 | .139 |
| Ertapenem | 3.02 | −0.09 | −.47 to .29 | .656 | −0.02 | 0.03 | .02 to .05 | <.001 |
| . | Intercept Parameters (Indicative of Immediate Change) . | Slope Parameters (Indicative of Long-Term Change) . | ||||||
|---|---|---|---|---|---|---|---|---|
| Antibiotic . | Baseline Value . | Calculated Change . | 95% CI . | P Value . | Baseline Value . | Calculated Change . | 95% CI . | P Value . |
| Targeted antibiotics | ||||||||
| Daptomycin | 6.18 | −0.89 | −1.38 to −.41 | <.001 | −0.01 | 0.01 | −.01 to .03 | .291 |
| Linezolid | 6.21 | −0.89 | −1.27 to −.52 | <.001 | −0.01 | 0.00 | −.01 to .02 | .741 |
| Meropenem | 7.58 | −0.97 | −1.39 to −.56 | <.001 | −0.01 | 0.00 | −.01 to .02 | .669 |
| Tigecycline | 9.03 | −1.41 | −2.19 to −0.63 | .001 | 0.00 | −0.01 | −.03 to .02 | .724 |
| Vancomycin | 4.63 | 0.09 | −.10 to .29 | .342 | −0.01 | −0.04 | −.01 to .00 | .313 |
| Nontargeted antibiotics | ||||||||
| Cefepime | 5.34 | 0.15 | −.09 to .39 | .216 | −0.01 | −0.01 | −.02 to −.00 | .047 |
| Ceftazidime | 8.26 | −0.67 | −2.00 to .66 | .322 | 0.04 | −0.03 | −.08 to .15 | .177 |
| Piperacillin-tazobactam | 5.62 | −0.08 | −.31 to .16 | .523 | −0.02 | 0.01 | .00 to .02 | .139 |
| Ertapenem | 3.02 | −0.09 | −.47 to .29 | .656 | −0.02 | 0.03 | .02 to .05 | <.001 |
All values correspond to a linear combination of parameter estimates for the before and after values of the segmented regression analysis.
Abbreviation: CI, confidence interval.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
